[Medical oncology].
The 2006 vintage leads to decreased enthusiasm in medical oncology, compared to the amazing 2005. One notable exception is the marketing of sunitinib and sorafenib, two agents which increase remarkably the chances of benefiting renal cell cancer patients. Several of the reviewed papers indicate the need to better target cancer treatment, including chemotherapy. One may hope that the near future will deliver on this, leading to an increased treatment effectiveness and decreased exposure to unjustified toxicity.
Aapro
M S
MS
Clinique de Genolier, 1272 Genolier. maapro@genolier.net
D001943:Breast Neoplasms / Q000188:drug therapy*; D015179:Colorectal Neoplasms / Q000628:therapy*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*